Shay Shemesh - 16 May 2022 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Role: Chief Dev. & Ops. Officer
Signature: /s/ Shay Shemesh
Issuer symbol: NVCT
Transactions as of: 16 May 2022
Net transactions value: +$4,704
Form type: 4
Filing time: 18 May 2022, 08:31:24 UTC
Previous filing: 13 May 2022
Next filing: 23 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCT	Common Stock	Purchase	$1,928	+100	+0.01%	$19.28	1,240,993	16 May 2022	Direct	F1
transaction	NVCT	Common Stock	Purchase	$2,776	+142	+0.01%	$19.55	1,241,135	17 May 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 48,399 shares of restricted stock and 60,000 restricted stock units.
F2	Reflects the weighted average purchase price. The range of prices for the shares purchased was $19.23 to $19.94. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

Content

Includes 48,399 shares of restricted stock and 60,000 restricted stock units.

Reflects the weighted average purchase price. The range of prices for the shares purchased was $19.23 to $19.94. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.